Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sorivudine (BV-araU) has antiviral activity against several viruses including varicella zoster virus, herpes simplex type 1 virus, and Epstein-Barr virus by interfering with viral DNA synthesis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 54.00 | |
5 mg | In stock | $ 129.00 | |
10 mg | In stock | $ 192.00 | |
25 mg | In stock | $ 329.00 | |
50 mg | In stock | $ 488.00 |
Description | Sorivudine (BV-araU) has antiviral activity against several viruses including varicella zoster virus, herpes simplex type 1 virus, and Epstein-Barr virus by interfering with viral DNA synthesis. |
In vitro | Sorivudine inhibits strains of HSV-1 and HSV-2 (ID50s (50% inhibitory dose): 0.39 and 0.67 μM, respectively). Sorivudine has antiviral activity against several viruses including varicella-zoster virus, herpes simplex type 1 virus, and Epstein-Barr virus. Sorivudine has in vitro inhibitory activity against the varicella-zoster virus at concentrations of 00001-0.004 mg/ml. These concentrations are over 1000-fold lower than those which are required for the inhibition of VZV replication by acyclovir 3 Sorivudine also inhibits HSV-I replication at concentrations ranging from 0.03-0.1 mg/ml [1][2]. |
In vivo | Sorivudine has been evaluated in the treatment of HSV-l encephalitis when administered orally to mice. The survival of treated mice is prolonged at dosages in excess of 12.5 mg/kg. A significant decrease in mortality was achieved as well with doses in excess of 50 mg/kg. Sorivudine therapy at dosages as low as 20 mg/kg per day given intramuscularly or 100 mg/kg per day administered orally completely protected against viremia and mortality. There was no evidence of neurotoxicity or abnormalities in hematology or clinical chemistries. Doses as low as 0.2 mg/kg per day were effective; however, breakthrough viremia was noted at lower dosages [2]. |
Synonyms | BV-araU |
Molecular Weight | 349.13 |
Formula | C11H13BrN2O6 |
CAS No. | 77181-69-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (358.03 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Sorivudine 77181-69-2 Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA/RNA Synthesis nucleoside antiviral inhibit antimetabolite Epstein-Barr pyrimidine virus zoster oral varicella Inhibitor BV-araU herpes simplex type inhibitor